Sweden's Oncopeptides Q3 net sales rise on Pepaxti demand

Oncopeptides AB

05/11/2026 07:15

Overview
Sweden biotech firm's Q3 net sales rose 41% yr/yr on Pepaxti growth in Europe
Company's Q3 operating and net losses narrowed from a year earlier
Company received CHMP positive opinion for Pepaxti label expansion in myeloma

Outlook
Company did not provide specific financial guidance or outlook for the current or future periods in its press release
Company expects European Commission decision on Pepaxti third-line approval in Q4
Company aims to achieve positive cash flow from Pepaxti commercialization in 2027

Result Drivers
PEPAXTI SALES GROWTH - Co said Q3 sales growth was driven by increased demand for Pepaxti in Europe
SEASONAL IMPACT - Co said European summer vacation period led to softer demand in August and September
ITALY OUTPERFORMANCE - Co said Italy exceeded expectations due to established market access and strong patient identification

Company press release: ID:nMFN7Hcvn7

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Sales
 
SEK 28.45 mln
 
Q3 Adjusted Loss Per Share
 
SEK 0.12
 
Q3 Net Loss
 
SEK 43.97 mln
 
Q3 Cash Flow from operating activities 
 
-SEK 37.71 mln
 
Q3 Operating Profit
 
-SEK 36.47 mln
 

Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Oncopeptides AB is SEK2.50, about 45% above its November 4 closing price of SEK1.72

Reuters Recommended Reads
Nov 5 - Sweden's Camurus Q3 revenue beats estimates on Buvidal, Brixadi growth
Nov 3 - Mirum Pharmaceuticals Q3 net product sales surge, outlook raised
Nov 3 - Zevra Therapeutics Q3 revenue rises 45% on MIPLYFFA sales

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)